Mexico City, Mexico, February 25, 2016

Genomma Lab Internacional, S.A.B. de C.V. **(BMV: LAB.B)** ("Genomma Lab" or "the Company"), announced today its results for the fourth quarter and full year ended December 31, 2015. All figures included herein are stated in nominal Mexican pesos and were prepared in accordance with International Financial Reporting Standards (IFRS).

Q4 2015 Highlights (vs. Q4 2014)

- Net Sales for the fourth quarter reached Ps. 2.67 billion; 2.9% above the Company guidance for the quarter, representing a 5.9% decrease compared to the same period of 2014. Net sales by region were:
  - Sales from our LatAm operations increased 37.1% to Ps. 1.44 billion as compared to Ps. 1.05 billion in the fourth quarter 2014.
  - Sales from our Mexican operations were Ps. 929.3 million, declining 34.7% as compared to the fourth quarter 2014, in line with our channel inventory destocking process.
  - Sales from our U.S.A. operations amounted to Ps. 305.8 million, representing a decline of 17.5% compared to the same period of 2014, and 9.2% above our guidance for the quarter
- EBITDA including non-recurring cash charges and one-time non-cash items was negative Ps. 2.28 billion. The Adjusted[1] EBITDA was Ps. 279.3 million and Adjusted EBITDA margin for the quarter was 10.4%.

Full year 2015 Highlights (vs. 2014)

- Net Sales for the year reached Ps. 11.04 billion, decreasing 4.3% compared to 2014, and 1.1% above the Company guidance for the quarter.
  - Sales from our LatAm operations increased 25.9% to Ps. 5.85 billion compared to 2014.
  - Sales from our Mexican operations were Ps. 3.92 billion, declining 35.9% as compared to 2014.
  - Sales from our U.S.A. operations increased 62.4% to Ps. 1.27 billion.

- Reported EBITDA was negative Ps. 857.0 million and Adjusted EBITDA margin for the year was 16.3%; 0.1 percentage points below our guidance for the year on an Adjusted EBITDA of Ps. 1.80 billion.

[1] EBITDA was adjusted by adding restructuring non-recurring charges, as well as non-cash one-time charges derived from strengthening policies.

The Company announced a strategy in the third quarter 2015 to turn around its Mexican operations, diversify its geographic presence, focus on core brands, streamline operations and set a course for long term profitability. The three primary phases of the strategy are described below, and the results for the fourth quarter and full year 2015 reflect the implementation of actions taken during this process.

Turnaround Process

Strategic Imperatives	• **Shareholder value creation** • **Sustainable business model and stronger brands** • **International expansion** • **Less dependence on Mexico**
Pillars of New Strategy	• **Brands:** Focus on core brands, reinforce brand equity and sustainability • **Mexico:** Destocking of channel inventory • **Geographical presence:** International growth and margin expansion - diversify away from Mexico • **Efficiency:** SG&A leverage • **New management team** to execute the new strategy and drive value creation in this new phase
Stronger policies & disclosure	• **Strengthening of corporate policies and procedures resulted in primarily non-cash, one-off effects** in Q4 and FY2015 results • **Tightened policies and procedures with additional oversight to support the future strategy**

Comments from the CEO

Mr. Máximo Juda, Chief Executive Officer, said: “2015 represented an important turning point for Genomma Lab. We began the year by implementing a new commercial strategy targeted at strengthening our business model in Mexico while continuing to successfully grow our international business. We also streamlined our brand portfolio through a renewed focus on our core products. On June 22, we announced the sale of Marzam, which improved our capital structure through the prepayment of Ps. 950.0 million in debt. At the end of the year, our net debt stood at Ps. 4.45 billion, a reduction of 22.2% from where it stood at the end of 2014. Throughout the year we continued to build our management capabilities, and I am confident that we have the right team in place to keep Genomma on course to achieve long-term sustainable growth, profitability and shareholder value.

In the fourth quarter, we took several very tough decisions to ensure that Genomma is utilizing sound accounting policies that navigate new challenging conditions. Our new CFO evaluated the policies and procedures we had in place. We found them inadequate under the current circumstances, and took immediate steps to reassess the underlying assumptions. These actions, which we believe are in the best interest of long-term value creation for our shareholders, caused us to record both non-recurring cash charges and one-time non-cash items in the fourth quarter. We will detail the financial impacts of the charges in the report below. While the effect of these charges significantly reduced our reported results for the fourth quarter and full year 2015, they did not impair the underlying health of our business – rather, the new policies in place have strengthened Genomma's operations.

Our new management team has re-set the bar and is successfully executing on the turnaround strategies that we announced in the third quarter. Along with the new management team and efficiency-driven SG&A leverage across the organization, the strategy is based on the following pillars:

- First, building and leveraging the brand equity of our core brands;
- second, implementing efficiency and margin improvements, and significant channel inventory destocking in Mexico that will result in an improved cash conversion cycle and free cash flow generation; and,
- finally, driving international growth and margin expansion, particularly in the U.S. where we've quickly become an important player in the general market with POS in Walgreens, Walmart, CVS, Target, Rite Aid and Kroger- and an important driver of share increase among Hispanics at those retailers.

Genomma's underlying performance in the fourth quarter and full year 2015 reflects the advances we've already made during the first two phases of this turnaround strategy. During the final quarter of the year we achieved Ps. 2.67 billion in Net Sales; exceeding our guidance by 2.9%, and for the full year Net Sales were Ps. 11.04 million, also slightly ahead of the guidance we provided to the market by 1.1%. It's important to note that the 4.3% year on year decline in the full year Net Sales was due to reduced sales from Mexico, which was in line with our destocking strategy. Genomma's international operations posted a strong 31.1% increase in sales for the year and now accounts for 64.5% of our total revenues. We also saw fourth quarter EBITDA margin improvement in Latin America despite headwinds in a number of our key markets.

The strategy we have in place and the extensive review of operations have resulted in the prudent changes to our accounting policies which better reflect our current business. Our continued progress, combined with the conservative approach we've adopted, will provide a strong foundation for the Company's future growth.

Looking ahead, we expect Genomma's turnaround process to conclude by the end of 2016 and the channel destocking process to conclude by the second quarter of 2016, resulting in a strengthened business model, stronger brands, increased penetration in the international markets and, improved shareholder value."

A) Consolidated Results of Operations for the Fourth Quarter and Full year 2015 – Reported and Adjusted "like-for-like"

The following tables show consolidated results of operations on an as reported basis and adjusted for restructuring non-recurring charges and one-time charges for comparative purposes, in millions of pesos. Margins are shown as a percentage of Net Sales. All figures for 2015 are compared to the same period of the previous year:

For the fourth quarter and full year ended December 31, 2015 and 2014
(In million pesos)

Q4		REPORTED		ADJUSTED "Like-for-Like"	
	Q4 2014	Reported Q4 2015	*Variation vs Q4'14*	Adjusted Q4 2015	*Variation vs Q4'14*
Net Sales	**2,843.3**	**2,675.0**	*-5.9%*	**2,675.0**	*-5.9%*
Gross Profit	**1,978.8**	**1,428.3**	*-27.8%*	**1,855.1**	*-6.3%*
Gross Margin	*69.6%*	*53.4%*		*69.3%*	
EBITDA[1]	**703.3**	**-2,280.8**	*-424.3%*	**279.3**	*-60.3%*
EBITDA Margin	*24.7%*	*-85.3%*		*10.4%*	
Operating Income	674.4	-2,314.0	*-443.1%*	246.2	*-63.5%*
Operating Margin	*23.7%*	*-86.5%*		*9.2%*	
Net Income of Majority Shareholders	510.6	-1,747.8	*-442.3%*		
Net margin	18.0%	-65.3%			
Weighted average number of shares outstanding	1,047,022,413	1,014,583,151			
EPS 12 months[2]	1.38	- 1.05			

Full Year	FY 2014	REPORTED: Reported FY 2015	REPORTED: Variation vs FY'14	ADJUSTED "Like-for-Like": Adjusted FY 2015	ADJUSTED "Like-for-Like": Variation vs FY'14
Net Sales	**11,541.0**	**11,042.5**	*-4.3%*	**11,042.5**	*-4.3%*
Gross Profit	**8,002.2**	**7,265.4**	*-9.2%*	**7,692.1**	*-3.9%*
Gross Margin	*69.3%*	*65.8%*		*69.7%*	
EBITDA[1]	**2,543.1**	**-857.0**	*-133.7%*	**1,798.0**	*-29.3%*
EBITDA Margin	22.0%	-7.8%		16.3%	
Operating Income	2,445.1	-975.2	*-139.9%*	1,679.8	*-31.3%*
Operating Margin	21.2%	-8.8%		15.2%	
Net Income of Majority Shareholders	1,444.6	-1,068.5	*-174.0%*		
Net margin	12.5%	-9.7%			
Weighted average number of shares outstanding	1,048,254,860	1,031,553,476			
EPS 12 months[2]	1.38	- 1.04			

[1] EBITDA is calculated by adding depreciation and amortization to the Operating Income.
[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of December 31, 2015 is 1,013,216,902.
Note: "Like-for-like" results were adjusted by adding restructuring non-recurring charges, as well as non-cash one-time charges derived from strengthening policies, both in Q4 and prior quarter of 2015.

B) Non-recurring charges recorded in the Fourth Quarter 2015

The Company continued its restructuring process in Mexico, and strengthened its financial policies and procedures. Accordingly, two types of adjustments were made during the fourth quarter, the vast majority of which were **non-cash** one-time charges, as well as other non-recurring cash restructuring charges.

B.1) Restructuring non-recurring charges in Q4 and FY 2015 (Cash items)

Non-recurring restructuring charges in Mexico total **Ps. 237.0 million**. Key items are:

- **Severance payments and loss from litigation** during the quarter amounted to Ps. 57.4 million. These expenses were recorded as part of SGM&A.
- **Investment Banking, legal and other expenses related to the M&A transaction** derived from the sale of Grupo Marzam. These fees amount to a total of Ps. 34.7 million and are included in SGM&A.
- **Disposal of obsolete inventory and other non-recurring restructuring charges** amounted to a total of Ps. 144.5 million during the fourth quarter 2015 and is mainly due to inventory returned by Grupo Marzam that became obsolete and was disposed of in the fourth quarter as well as excess raw material stored previously by our manufacturing partners. This return was recorded as part of Cost of Goods Sold (COGS).

B.2) One-time charges derived from strengthening policies (Non-cash items)

The Company strengthened its financial policies and implemented additional procedures and controls in the fourth quarter resulting in the adjustments described below. We believe there are now adequate levels of reserves and that these policies reflect a **prudent**[1] accounting approach within the current circumstances. These policies were presented to and approved by the Audit Committee and the Board of Directors in order to enhance the relevance and reliability of information contained in the financial statements.

The following items are adjusted in the earnings report for the fourth quarter 2015: allowance for doubtful accounts, obsolete inventory reserve, provision for litigation costs, non-compete with wholesalers and distributors, intangible assets related to discontinued operations, impairment charges for other intangible assets and impairment for barter trade credits.

- **Allowance for doubtful Accounts** amounting to Ps. 737.9 million. This is a non-cash allowance in SGM&A. A more conservative approach to our expected collections from some clients resulted in more prudent estimation for this allowance.

  The prior Company policy allowed for discretionary adjustments to the allowance for doubtful accounts by the Accounts Receivable manager. During 2015, the situation was not adequately assessed by the Accounts Receivable manager, who is no longer with the Company. Additionally, the new policy excludes all discretionary aspects and objectively applies formulas to estimate the allowance for doubtful accounts, in line with best

[1] IASB considers that **prudence** (defined as the exercise of caution when making judgements under conditions of uncertainty) can help achieve neutrality in applying accounting policies. Another way of looking at prudence is to only record a revenue transaction or an asset when it is certain, and record an expense transaction or liability when it is probable.

industry practice. The Company recorded an allowance of 100% of the outstanding balance of clients who have gone out-of-business or who have not conducted business with the Company for the past 12 months and reinforced collection efforts via judicial procedures. As part of the new policy, the Company is now implementing more robust credit risk policies and procedures to prevent additional aging of existing customers accounts. These new procedures will be incorporated into the Company's ERP system, which is also being enhanced.

- **Obsolete Inventory Reserve** amounting to Ps. 299.1 million. The non-cash write down on inventory is recorded in Cost of Goods Sold. Accordingly, the Inventory balance was adjusted on the Balance Sheet.

  IFRS mandates immediate recognition of any obsolescence as soon as it is detected. During the third quarter 2015 the Company received back from Marzam the inventory of Genomma's finished goods as part of the Share Purchase Agreement. Given the current limited sell-in run rate, the Company believes there is an obsolescence risk for part of the returned finished goods inventory, as it will not be able to sell all of these items by the time they expire during the next three quarters. As of December 31, 2015, Grupo Marzam holds 67 days of inventory of our products.

  As part of the new Company policy, it is **prudent** to conduct more frequent obsolescence reviews, and maintain reserves based on historical or expected obsolescence, in particular while the destocking process takes place. Based on international best practice, the Company is disclosing the amount of the write-downs as a charge separately identified from the normal cost of goods sold (see "like-for-like").

- **Provision for Litigation Costs** amounting to Ps. 53.6 million. The non-cash provision is recorded as an SGM&A expense. Over the years, the Company had not lost any major court case, and as such, there was no provision for litigation costs. During the fourth quarter 2015 the Company had to pay Ps. 10.0 million in a judgment against it. In line with IAS-37, all court cases that may be reliably estimable and may constitute probable losses (more than 50% probability) are now provisioned.

- **Non-Compete with Wholesalers and Distributors** amounting to Ps. 418.8 million. These non-cash write-offs are related to non-compete agreements with wholesalers and distributors in new channels (including the traditional channel, liquidators and others) that have not operated with the Company during the last twelve months.

- **Intangible Assets Related to Discontinued Operations** amounting to Ps. 467.0 million. These non-cash write-offs are related to non-compete agreements of discontinued operations. For example, the Company no longer operates the business unit in charge of generic medicines that acquired some of these agreements. This charge also includes impairments on manufacturing know-how.

- **Impairment of Barter Trade Credits and Other Estimates.** The Company holds non-monetary assets for barter trade credits[2] with Active International. Some of these credits have been bartered for media services in the past. However, the Company estimates that it may not be able to convert the barter credits in the near term, as evidenced by historical data (the last transaction in the amount of Ps. 1.0 million took place in January 2015). An impairment loss of Ps. 346.6 million is recognized as it is probable that the Company will not use all of the remaining barter credits. Despite this impairment, the Company will make its best effort to convert these Barter Credits into cash in the future.

Upon completion of the audited full year 2015 results, we will also file the favorable opinion already provided by the auditors related to changes in our policies.

Despite these write-offs, it is worth mentioning that the Company holds internally-developed brands and other intangibles, which produce economic benefits to its shareholders. Following accounting principles, the fair value of these internally-developed intangibles is not reflected in the Balance Sheet. Should the Company decide to sell any of these intangible assets, additional sources of income would be obtained.

C) MD&A for the Fourth Quarter and Full Year 2015 Consolidated Results

Net Sales of Ps. 2.67 billion during the fourth quarter of 2015, 2.9% above the Company guidance, which represented a 5.9% decline quarter on quarter. For the full year, Net Sales were Ps. 11.04 billion, 1.1% above Guidance provided to the market, which represented a decline of 4.3% vs the prior year. Results by region were:

Latin America

Net Sales rose 37.1% to Ps. 1.44 billion in the fourth quarter of 2015 vs the prior year, in line with our guidance, with several countries recording strong double digit growth. The main drivers of growth were the addition of new channels, such as retail and specialty channels, new clients, product launches, as well as price increases.

For the full year, Net Sales in Latin America rose 25.9% to Ps. 5.85 billion, compared to Ps. 4.65 billion in 2014, in line with guidance.

As we move into 2016, Argentina is experiencing a major currency devaluation and Brazil continues to face market softness; these effects may have an impact on their results.

[2] For reference, see SIC-31 *Revenue – Barter Transactions Involving Advertising Services*

Mexico

Net Sales (sell-in) amounted to Ps. 929.3 million in the fourth quarter of 2015, which represented a 34.7% decrease compared to the fourth quarter of 2014. This was due to the Company's channel inventory destocking process. For the full year, Net Sales in Mexico amounted to Ps. 3.92 billion; 35.9% below 2014.

Sell-out during the quarter increased 2.5% vs the same quarter of last year, allowing the inventory reduction at the point of sale to continue. It will take at least two more quarters for the destocking process to be completed.

U.S.A.

Net Sales were 9.2% above our guidance, amounting to Ps. 305.8 million during the fourth quarter of 2015. The expected decline of 17.5% in sales quarter-on-quarter resulted from lapping the commercial expansion into Walgreens and Walmart last year, where growth was 107% and 49%, respectively, as compared to the same period in 2013. For the full year, Net Sales in the U.S.A. rose 62.4% to Ps. 1.27 billion, compared to Ps. 784.0 million in 2014. These results were 2.2% above our annual guidance.

Net Sales Reported by Region and Segment



(In million pesos)

	4Q15			4Q14			
	OTC	PC	Total 4Q15	OTC	PC	Total 4Q14	%Var
Mexico	556.7	372.6	**929.3**	948.5	474.2	**1,422.6**	-34.7%
LATAM	405.5	1,034.4	**1,439.9**	268.6	781.3	**1,049.9**	37.1%
EUA	193.6	112.2	**305.8**	205.5	165.2	**370.8**	-17.5%
TOTAL	**1,155.7**	**1,519.2**	**2,675.0**	**1,422.6**	**1,420.8**	**2,843.3**	**-5.9%**

	2015			2014			
	OTC	PC	Total 2015	OTC	PC	Total 2014	%Var
Mexico	2,071.8	1,846.4	**3,918.2**	3,841.4	2,266.8	**6,108.2**	-35.9%
LATAM	1,672.1	4,178.6	**5,850.7**	1,207.3	3,441.5	**4,648.8**	25.9%
USA	829.1	444.4	**1,273.5**	449.0	335.0	**784.0**	62.4%
TOTAL	**4,573.0**	**6,469.5**	**11,042.5**	**5,497.7**	**6,043.3**	**11,541.0**	**-4.3%**

Gross Profit decreased 27.8% to Ps. 1.43 billion in the fourth quarter of 2015, compared to Ps. 1.98 billion during the fourth quarter of 2014. Gross Margin declined 16.2 percentage points to 53.4% in the fourth quarter of 2015. The gross margin reduction was primarily due to adjustments in Mexico for lower discounts recorded in previous quarters than were actually accepted by some of our clients. Adjusting for non-recurring charges, Gross Profit would have amounted to Ps. 1.85 billion in the quarter, and registered a Gross Margin of 69.3%

Gross Profit for the full year decreased 9.2% to Ps. 7.27 billion, compared to Ps. 8.00 billion during 2014. However, Adjusted Gross Margin remained stable at 69.7% in 2015.

Selling, General, Marketing and Administrative Expenses, excluding the Mexican operations, margin fell by 1.4 percentage points in 2015 compared to 2014, as a result of economies of scale achieved in certain countries, primarily Argentina.

SGM&A in Mexico increased as a percentage of sales as a result of maintaining advertising expenses as well as POS investments to support the sell-out level from our clients and the destocking process as part of the platform for Genomma's future growth. SGM&A in Mexico also included non-recurring or one-time charges such as allowance for doubtful accounts, provisions for litigation costs and impairment of barter trade credits.

Selling, General, Marketing and Administrative Expenses (including Depreciation and Amortization) for the full year, as a percentage of Net Sales, amounted to 66.4%, compared to 48.3% in 2014. Adjusting for the non-recurring and one-time charges, the SGM&A was 54.3%.

Other Income (Expenses) amounted to negative Ps. 898.3 million in the fourth quarter 2015 and include mainly non-cash non-recurring expenses derived from the impairment of intangible assets. Other expenses for the full year amounted to negative Ps. 906.5 million.

Adjusted EBITDA decreased 60.3% to Ps. 279.3 million in the fourth quarter of 2015, compared to Ps. 703.3 million in the fourth quarter of 2014. The Adjusted EBITDA margin decreased to 10.4% in the fourth quarter of 2015. The Adjusted EBITDA margin decrease was primarily due to higher Selling, General, Marketing and Administrative Expenses (excluding Depreciation and Amortization), as a percentage of Net Sales, as well as higher cost of goods sold, as a percentage of Net Sales.

Adjusted EBITDA for the full year reached Ps. 1.80 billion, representing a margin of 16.3%, compared to Ps. 2.54 billion in 2014, which represented a margin of 22.0%.

EBITDA Reconciliation

For the fourth quarter and full year ended December 31, 2015 and 2014
(In million pesos)

	Fourth Quarter		Full Year	
	2015	2014	2015	2014
Consolidated net income	(1,735.4)	488.3	(1,012.6)	1,494.2
Discontinued operations (income)	-	12.9	(68.2)	-
Income tax expense	(737.2)	170.4	(373.9)	623.6
Not consolidated subsidiaries' loss (income)	(15.8)	9.2	(12.0)	11.7
Comprehensive financing cost (income)	174.5	(6.5)	491.5	315.7
Operating income	**(2,314.0)**	**674.4**	**(975.2)**	**2,445.1**
Depreciation and amortization	33.1	28.8	118.2	98.0
EBITDA	**(2,280.8)**	**703.3**	**(857.0)**	**2,543.1**
EBITDA margin	*-85.3%*	*24.7%*	*-7.8%*	*22.0%*
Non-recurring expenses and one-off effects [1]	2,560.1	-	2,655.0	-
Adjusted EBITDA	**279.3**	**703.3**	**1,798.0**	**2,543.1**
Adjusted EBITDA margin	10.4%	24.7%	16.3%	22.0%

[1] Non-recurring expenses are related to the downsizing of our headcount in Mexico (severance payments) incurred during Q4´15 and full year 2015, and inventory destructions and fees and other expenses derived from the sale of Grupo Marzam during Q4´15. One-off effects are related to the reinforcement of policies and procedures during Q4´15.

Comprehensive Financing Result represented a loss of Ps. 174.5 million in the fourth quarter of 2015, compared to the Ps. 6.5 million gain recorded in the fourth quarter of 2014. This variation was a result of: i) a Foreign Exchange loss amounting to Ps. 4.3 million during the fourth quarter of 2015, compared to a Ps. 133.9 million gain during the same period of 2014; the result in this quarter was stable vs the previous quarter); ii) a decrease of Ps. 5.9 million in Financial Expenses to Ps. 84.9 million during the fourth quarter of 2015, compared to Ps. 90.8 million during the same period of 2014; iii) a lower Interest Income amounting to Ps. 2.8 million during the fourth quarter of 2015, compared to Ps. 3.9 million in the same period of 2014; and, iv) a Ps. 88.2 million loss in the fourth quarter of 2015 related to the Exchange Rate conversion from our foreign operations, compared to a Ps. 40.5 million loss in the same period of 2014.

Comprehensive Financing Result for the full year amounted to a loss of Ps. 491.5 million, which represented an increase of Ps. 175.8 million in the loss, compared to a Ps. 315.7 million loss recorded in 2014.

Net Income (Loss) amounted to a loss of Ps. 1.74 billion in the fourth quarter of 2015, compared to an income of Ps. 514.2 million in the fourth quarter of 2014.

Consolidated Net Income (Loss) for the full year amounted to a loss of Ps. 1.01 billion, compared to an income of Ps. 1.51 billion in 2014, which represented a margin of 13.1%. The consolidated tax rate for the full year 2015 was 25.7%, consisting of a 31.2% tax rate in Mexico and a 36.1% tax rate in the international operations.

Cash flow for the Fourth quarter and Full year 2015

For the fourth quarter and full year ended December 31, 2015 and 2014
(In million pesos)

	December 2015	
	4Q15	Full Year
Net Income	(1,735,444)	(1,012,636)
Charges to Results with no Cash Flow	(1,479,015)	(94,180)
Changes in Working Capital	1,426,804	1,232,514
Net Cash from Operating Activities	**(52,211)**	**1,138,334**
Purchase of Property, Plant & Equipment	(31,115)	(42,550)
Purchase of Businesses and Others	(52,411)	966,072
Net Cash from Investing	**(83,526)**	**923,522**
Proceeds (Repayment) of Borrowing	81,161	(718,982)
Financing Expenses/Income and Other	(348,082)	(873,432)
Net Cash from Financing	**(266,921)**	**(1,592,414)**
Effect of Exchange Rate Changes on Cash	12,292	74,166
Minus Restricted Funds	(52,069)	(52,069)
Cash at Beginning of Period	2,116,270	1,182,296
Cash at End of Period	**1,673,835**	**1,673,835**

Cash Flow from Operations

Net resources used in operating activities amounted to Ps. 52.2 million in the fourth quarter of 2015 primarily due to a change in policies with customers in Mexico where we are no longer providing disadvantageous discounts for advance payments.

For the full year, net resources from operating activities amounted to Ps. 1.14 billion.

Cash Flow from Financing Activities

In the fourth quarter of 2015, the Company paid a total of Ps. 266.9 million related to financing activities, derived from stock repurchases amounting to Ps. 272.3 million, payments of debt with financial institutions amounting to Ps. 189.7 million and interest paid amounting to Ps. 78.8 million, which were offset by an increase in debt amounting to Ps. 270.9 million in our Brazil operations that will be fully repaid by June of 2016.

For the full year, net resources from financing activities amounted to Ps. 1.59 billion.

Cash Flow from Investing Activities

Net resources used in investing activities in the fourth quarter of 2015 amounted to Ps. 83.5 million, primarily related to CAPEX. This amount is in line with our strategy to reduce investments, mainly in brand acquisitions.

For the full year, net resources from investing activities amounted to Ps. 923.5 million.

Balance Sheet

As of December 31, 2015, December 31, 2014 and September 30, 2015
(In millions of current Mexican pesos)

	December 31, 2015	December 31, 2014	Var Dec '15 vs Dec '14	% Var Dec '15 vs Dec '14	September 30, 2015	Var Dec '15 vs Sep '15	% Var Dec '15 vs Sep '15
Balance Sheet Information:							
Cash and Equivalents	**1,725.9**	1,182.3	543.6	46.0%	2,116.3	(390.4)	-18.4%
Accounts Receivable	**2,072.6**	4,164.3	(2,091.7)	-50.2%	3,034.9	(962.3)	-31.7%
Inventories	**1,158.9**	1,595.0	(436.1)	-27.3%	1,544.4	(385.5)	-25.0%
Other current Assets	**2,581.6**	10,196.6	(7,615.0)	-74.7%	4,112.8	(1,531.2)	-37.2%
Fixed, Intangible and other LT Assets	**10,094.2**	8,290.1	1,804.1	21.8%	9,724.0	370.2	3.8%
Total Assets	**17,633.2**	25,428.3	(7,795.2)	-30.7%	20,532.4	(2,899.2)	-14.1%
Suppliers	**670.1**	1,554.7	(884.6)	-56.9%	1,100.6	(430.5)	-39.1%
Other current Liabilities	**1,475.1**	5,640.6	(4,165.5)	-73.8%	1,605.7	(130.6)	-8.1%
Current portion of debt	**350.9**	400.6	(49.7)	-12.4%	252.4	98.5	39.0%
Unsecured local bonds	**5,487.0**	5,481.7	5.3	0.1%	5,485.6	1.3	0.0%
Long-term loans with financial institutions	**342.3**	1,023.6	(681.3)	-66.6%	361.5	(19.2)	-5.3%
Total Liabilities	**8,384.5**	14,925.2	(6,540.7)	-43.8%	9,486.4	(1,101.9)	-11.6%
Stockholders Equity	**9,248.6**	10,503.1	(1,254.5)	-11.9%	11,046.0	(1,797.3)	-16.3%
Working Capital [1]	**5,042.9**	9,542.3	(4,499.4)	-47.2%	7,849.7	(2,806.7)	-35.8%
Working Capital less cash	**3,317.0**	8,360.0	(5,043.0)	-60.3%	5,733.4	(2,416.4)	-42.1%
Clients days	**68**	130	(62)	-48.0%	97	(29)	-30.7%
Inventories days	**110**	162	(52)	-31.9%	164	(54)	-32.6%
Suppliers days	**64**	158	(94)	-59.6%	117	(53)	-45.3%
Cash Conversion Cycle	**114**	134	(20)	-14.8%	144	(30)	-20.7%

[1] Working Capital consists of current assets minus current liabilities.

Cash and Equivalents amounted to Ps. 1.73 billion as of December 31, 2015, representing an increase of 46.0% compared to Ps. 1.18 billion as of December 31, 2014. This increase was primarily due to cash generated from our operations during the last twelve months.

In the fourth quarter of 2015, the Company repurchased Ps.272.3 million in shares and by year-end it reduced its cash discounts. As a result of this, Cash and Equivalents decreased Ps. 390.4 million compared to the previous quarter.

Accounts Receivable amounted to Ps. 2.07 billion as of December 31, 2015; a decrease of Ps. 2.09 billion vs December 2014. This improvement was driven by three factors: a) significant improvement in collections in our international operations, b) increase in the non-cash allowance for doubtful accounts, and was partially offset by c) the reduction of substantial cash discounts in our Mexican operations.

For comparison purposes, DSO at Genomma's operations improved from 130 days to 91 days, excluding the non-cash allowance. DSO decreased to 68 days once the Company's new financial policies were implemented.

Accounts Receivable as of December 2015 by region were:

Accounts Receivable 2015	
Latam	65
Mexico	75
USA	61

Inventories amounted to Ps. 1.16 billion as of December 31, 2015, a decrease of Ps. 436.1 million vs December 2014. This improvement was driven by four factors: a) significant improvement in inventory management at the Company's international operations, b) lower procurement levels from Mexican operations, c) increase in the non-cash obsolete inventory reserve, and d) disposal of obsolete inventory.

For comparison purposes, DOI at Genomma's operations improved from 162 days to 128 days, excluding the non-cash reserve. DOI decreased to 110 days once the Company's new financial policies were implemented.

Other Current Assets amounted to Ps. 2.58 billion as of December 31, 2015; a decrease of Ps. 7.61 billion primarily driven by the sale of assets classified as held for sale from the Marzam transaction and the aforementioned impairment of barter trade credits.

Other Assets were impacted by one-time non-recurring adjustments as previously mentioned.

Trade Payables amounted to Ps. 670.1 million as of December 31, 2015, compared to Ps. 1.55 billion as of December 31, 2014. During 2015, DPO decreased from 158 to 68 as a result of temporarily reduced procurement levels from our Mexican operations. This situation will reverse once the destocking process has been completed.

Other Current Liabilities amounted to Ps. 1.48 billion as of December 31, 2015; a decrease of Ps. 4.17 billion primarily driven by the liabilities related to the Marzam transaction.

Financial Debt amounted to Ps. 6.18 billion as of December 31, 2015, compared to 6.91 billion in the same period of 2014 due to the repayment of bank debt with proceeds derived from the Marzam sale. The maturities of long-term debt begin in September of 2017.

Based on the Company's current cash position and on projected cash generation, Genomma Lab is in a healthy financial position to cover its debt obligations and does not foresee the necessity to raise more debt in the near future. In addition, it is important to note that the Company is not in risk of violating any covenants of its outstanding debt. Furthermore, the Company's three outstanding bonds have a long-maturity profile (September 2017, July 2018 and January 2020).

Cash Conversion Cycle reached 114 days at the end of the fourth quarter of 2015, compared to 134 days on December 2014.

Other Corporate Events

- The cash flow used to repurchase shares amounted to Ps. 272.3 million during the fourth quarter 2015.
- The Company is maintaining its 2016 Guidance in sales, EBITDA and free cash flow. However, projections may be impacted by volatility in key currencies. For Guidance purposes, below are the 2016 year-end currency FX rates (vs USD) in these countries:

Argentina	15.8
Brazil	4.1
Colombia	3,338.0

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Genomma Lab relies on the combination of a successful new product development process, a consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Investor Relations
Tel: +52 (55) 5081-0000 Ext. 4016
E-mail: inversion@genommalab.com

In New York:
Barbara Cano, MBS Value Partners
Tel: +1 (646) 452-2334, E-mail: barbara.cano@mbsvalue.com

Income Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the twelve and three months ended on December 31, 2015 and 2014

(In thousands of current Mexican pesos)

	FOURTH QUARTER			ACCUMULATED		
	2015	2014	Var %	2015	2014	Var %
Net Sales	2,674,988	2,843,329	(5.9%)	11,042,451	11,540,998	(4.3%)
Cost of goods sold	1,246,671	864,523	44.2%	3,777,058	3,538,831	6.7%
Gross Income	**1,428,317**	**1,978,806**	**(27.8%)**	**7,265,393**	**8,002,167**	**(9.2%)**
Selling, general and administrative expenses	2,810,840	1,271,673	121.0%	7,215,923	5,471,237	31.9%
Other expenses	901,837	6,214	14413.0%	913,654	8,764	10325.1%
Other income	3,511	2,339	50.1%	7,195	20,951	(65.7%)
EBITDA	**(2,280,849)**	**703,258**	**(424.3%)**	**(856,989)**	**2,543,117**	**(133.7%)**
Depreciation and amortization	33,115	28,831	14.9%	118,232	98,021	20.6%
(Loss) income from Operations	**(2,313,964)**	**674,427**	**(443.1%)**	**(975,221)**	**2,445,096**	**(139.9%)**
Interest expense	(84,903)	(90,757)	(6.5%)	(392,562)	(360,003)	9.0%
Interest income	2,836	3,862	(26.6%)	20,586	11,827	74.1%
Exchange (expense) income	(92,469)	93,389	(199.0%)	(119,512)	32,525	(467.4%)
Comprehensive financing income (cost)	**(174,536)**	**6,494**	**(2787.7%)**	**(491,488)**	**(315,651)**	**55.7%**
Associated company	15,832	(9,205)	(272.0%)	12,024	(11,684)	(202.9%)
(Loss) income before income taxes	**(2,472,668)**	**671,716**	**(468.1%)**	**(1,454,685)**	**2,117,761**	**(168.7%)**
Income tax expense	(737,223)	170,447	(532.5%)	(373,895)	623,598	(160.0%)
Income from continuing operations	**(1,735,445)**	**501,269**	**(446.2%)**	**(1,080,790)**	**1,494,163**	**(172.3%)**
Net income from discontinued operations	-	12,943	(100.0%)	68,154	12,943	426.6%
Consolidated net income	**(1,735,445)**	**514,212**	**(437.5%)**	**(1,012,636)**	**1,507,106**	**(167.2%)**
Net income of minority stockholders	12,366	3,605	243.0%	55,882	62,548	(10.7%)
Net income of majority stockholders	(1,747,811)	510,607	(442.3%)	(1,068,518)	1,444,558	(174.0%)

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

As of December 31, 2015 and 2014 and December 31, 2014

(In thousands of current Mexican Pesos)

	DECEMBER		VARIATION		SEPTEMBER	VARIATION	
ASSETS	2015	2014	Amount	%	2014	Amount	%
Current assets							
Cash and equivalents	1,673,835	1,164,454	509,381	44%	2,098,999	(425,164)	(20%)
Restricted fund	52,069	17,842	34,227	192%	17,271	34,798	201%
Clients - Net	2,072,566	4,164,311	(2,091,745)	(50%)	3,034,867	(962,301)	(32%)
Others accounts receivable	1,846,954	1,307,094	539,860	41%	2,143,486	(296,532)	(14%)
Inventory - Net	1,158,913	1,595,012	(436,099)	(27%)	1,544,449	(385,536)	(25%)
Prepaid expenses	734,664	1,098,990	(364,326)	(33%)	1,969,325	(1,234,661)	(63%)
Assets classified as held for sale	-	7,790,506	(7,790,506)	(100%)	-	-	-
Total current assets	**7,539,001**	**17,138,209**	**(9,599,208)**	**(56%)**	**10,808,397**	**(3,269,396)**	**(30%)**
Non-current assets							
Trademarks	6,348,973	6,928,043	(579,070)	(8%)	7,057,934	(708,961)	(10%)
Investment in shares	1,352,478	18,360	1,334,118	7266%	1,367,140	(14,662)	(1%)
Building, properties and equipment – Net	406,646	457,659	(51,013)	(11%)	407,291	(645)	(0%)
Deferred income tax	323,435	79,233	244,202	308%	76,989	246,446	320%
Other assets - Net	1,662,626	806,811	855,815	106%	814,630	847,996	104%
Total non-current assets	**10,094,158**	**8,290,106**	**1,804,052**	**22%**	**9,723,984**	**370,174**	**4%**
			-				
TOTAL ASSETS	**17,633,159**	**25,428,315**	**(7,795,156)**	**(31%)**	**20,532,381**	**(2,899,222)**	**(14%)**

LIABILITIES AND STOCKHOLDERS' EQUITY	2015	2014	Monto	%	2015	Monto	%
Current Liabilities							
Current portion of long-term debt	350,884	400,579	(49,695)	(12%)	252,432	98,452	39%
Suppliers	670,116	1,554,690	(884,574)	(57%)	1,100,611	(430,495)	(39%)
Due to related parties	13,134	-	13,134	100%	12,495	639	5%
Other current liabilities	1,250,852	1,012,915	237,937	23%	1,323,388	(72,536)	(5%)
Income tax payable	184,285	126,477	57,808	46%	252,326	(68,041)	(27%)
Statutory employee profit sharing	26,797	13,827	12,970	94%	17,462	9,335	53%
Debts classified as held for sale	-	4,487,400	(4,487,400)	(100%)	-	-	-
Total current liabilities	**2,496,068**	**7,595,888**	**(5,099,820)**	**(67%)**	**2,958,714**	**(462,646)**	**(16%)**
Non-current liabilities							
Long-term debt securities	5,486,964	5,481,665	5,299	0%	5,485,639	1,325	0%
Long-term loans with financial institutions	342,266	1,023,613	(681,347)	(67%)	361,504	(19,238)	(5%)
Other long term liabilities	54,442	64,820	(10,378)	(16%)	53,984	458	1%
Deferred income tax	1,695	756,924	(755,229)	(100%)	623,682	(621,987)	(100%)
Employee retirement obligations	3,073	2,298	775	34%	2,879	194	7%
Total liabilities	**8,384,508**	**14,925,208**	**(6,540,700)**	**(44%)**	**9,486,402**	**(1,101,894)**	**(12%)**
Stockholders' equity							
Capital stock	1,914,306	1,914,306	-	-		1,914,306	100%
Retained earnings	8,263,564	6,819,006	1,444,558	21%	1,914,306	6,349,258	332%
Net income	(1,068,518)	1,444,558	(2,513,076)	(174%)	8,263,564	(9,332,082)	(113%)
Cumulative translation effects of foreing subsidiaries	417,750	149,561	268,189	179%	679,293	(261,543)	(39%)
Share buy back fund	(578,955)	(74,394)	(504,561)	678%	372,433	(951,388)	(255%)
Net premium in placement of repurchased shares	39,749	39,749	-	-	(468,688)	508,437	(108%)
Minority interest	260,755	210,321	50,434	24%	39,749	221,006	556%
Total stockholders' equity	**9,248,651**	**10,503,107**	**(1,254,456)**	**(12%)**	**245,322**	**9,003,329**	**3670%**
TOTAL EQUITY AND LIABILITIES	**17,633,159**	**25,428,315**	**(7,795,156)**	**(31%)**	**11,045,979**	**7,901,435**	**72%**

Cash Flow

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

For the twelve and three months ended on December 31, 2015

(In thousands of current Mexican pesos)

	DECEMBER 2015	
	4th QUARTER	ACCUMULATED
Cash and cash equivalents beginning of period	**2,116,270**	**1,182,296**
Consolidated Net Income	**(1,735,444)**	**(1,012,636)**
Charges to results with no cash flow:		
Depreciation and amortization	33,116	118,233
Income tax	(737,222)	(373,895)
Impairment of brands and long-lived assets	899,613	899,613
Accrued interest and others	60,922	274,505
	(1,479,015)	**(94,180)**
Changes in Working Capital:		
Clients - Net	962,389	2,091,831
Inventories	385,535	436,100
Suppliers	(430,735)	(885,250)
Other current assets	531,481	(885,197)
Payed income tax	(123,798)	(456,124)
Other current liabilities	101,932	259,894
Variation in assets available for sale	-	671,260
	1,426,804	**1,232,514**
Net cash generated (used) in operating activities	**(52,211)**	**1,138,334**
Investing activities:		
Investment in fixed assets	(32,592)	(63,376)
Sales of equipment	1,477	20,826
Brand acquisitions and others	(22,012)	(36,619)
Net cash outflow on acquisitions of subsidiary	(12,172)	(12,172)
Disposals of assets available for sale	-	1,050,000
Others assets acquisitions	(18,227)	(35,137)
Net cash generated (used) in investing activities	**(83,526)**	**923,522**
Financing activities:		
Payments of borrowings with financial institutions	(189,713)	(1,705,734)
Loans with financial and securities institutions	270,874	986,752
Interest paid	(78,830)	(343,257)
Stock repurchase	(272,318)	(524,727)
Minority interest	3,066	(5,448)
Net cash used in financing activities	**(266,921)**	**(1,592,414)**
Net increase in cash and cash equivalents before foreign exchange adjustments coming from international operations and inflationary affects cash	**(402,658)**	**469,442**
Foreign exchange and inflationary effects from international operations	12,292	74,166
Accumulated cash flow at the end of the period	**1,725,904**	**1,725,904**
Less - restricted fund	52,069	52,069
Cash and cash equivalents at end of period balance for operation	**1,673,835**	**1,673,835**